Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Mass Balance and PK of [14C]-BI 409306 in Healthy Volunteers
NCT02597998Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Sep 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of osoresnontrine in schizophrenia and Alzheimer's disease (AD), sponsored by Boehringer Ingelheim. Primary endpoint: Mass Balance Recovery of Total Radioactivity in Urine and Faeces. Started Sep 2015; status: completed.
02
Drugs
osoresnontrine
03
Conditions
schizophreniaAlzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02597998.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02597998.